Life Sciences Emerging Companies + Venture Capital Technology Transactions
The MoFo BioMeter is an index that measures the health of the biotechnology industry. The BioMeter averages up-front payments in licensing, collaboration, and development agreements between biotechnology companies (broadly defined) and companies that pay for commercialization rights. We focus on up-front payments because they are the most concrete representation of the value of a development-stage asset, and also because in an era of constricted venture funding for unapproved therapeutics, up-front payments from collaboration agreements have become an increasingly necessary source of capital for companies to sustain their development efforts. The BioMeter also allows us to measure changes in the industry, or by sector, over time.
Interested in Receiving Future Issues?
Send an email to biometer@mofo.
For questions and to provide feedback please contact firstname.lastname@example.org
Stephen B. Thau (650) 813-5640 (202) 887-1571 email@example.com Aaron J. Schohn (415) 268-7451 firstname.lastname@example.org Masato Hayakawa 81 3 3214 6522 email@example.com Deirdre Moynihan 44 (20) 79204164 firstname.lastname@example.org Gordon A. Milner 852 2585 0808 email@example.com Michael J. O’Donnell (650) 813-5977 firstname.lastname@example.org
©1996-2016 Morrison & Foerster LLP. All rights reserved.